← Russell 3000 cross-section

TXG 10x Genomics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-07, not restated
Healthcare

Scale

Market cap
$8.4bn
Revenue TTM
$617m
Net income TTM
$-75m
Free cash flow
$121m
Composite score
Sector rank
#797

Valuation

P / E
EV / EBITDA
EV / sales
13.6
FCF yield
1.44%
Earnings yield vs 10-yr
-5.62pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-12.2%
EBITDA margin
-7.8%
ROE
-9.1%
ROIC
-11.4%
Revenue growth
-4.3%

Insider activity, last 90 days

Net open-market
$-6.74m
Buyers
0
Sellers
6

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

License and Royalty Revenue The Company has agreements with third parties that include up-front fees and royalties. The contract liabilities of $ 33.3 million and $ 34.4 million as of June 30, 2026 and December 31, 2025, respectively, primarily consisted of deferred revenue related to extended warranty service agreements. 10x Genomics, Inc. Net Income (Loss) Per Share The Company computes net income (loss) per share attributable to common stockholders using the two-class method required for multiple classes of common stock and participating securities. …10x Genomics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-07

Read the full passage →